It's TIME for a biomarker-driven approach to cancer immunotherapy

Journal for ImmunoTherapy of Cancer

Volumn 4, Issue 1, 2016, Pages

  Emens, Leisha A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BEVACIZUMAB; BIOLOGICAL MARKER; CANCER VACCINE; CD16 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; SIPULEUCEL T; TG 4010;

ADAPTIVE IMMUNITY; BLADDER CANCER; CANCER IMMUNOTHERAPY; GLOMERULUS FILTRATION RATE; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; MELANOMA; MICROSATELLITE INSTABILITY; MULTICENTER STUDY (TOPIC); NATURAL KILLER CELL; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; T LYMPHOCYTE;

EID: 84997707940     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0147-8     Document Type: Note

References (16)

1. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol. 2015;42:587-600.
2. Emens LA, Jaffee EM. Cancer vaccines: on the threshold of success. Cancer Biol Ther. 2003;2(Suppl1):S161-8.
3. Emens LA. Roadmap to a better therapeutic tumor vaccine. Intl Rev Immunol. 2006;25:415-43.
4. Emens LA, Silversten SC, Khleif S, Marincola FM, Galon J. Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med. 2012;10:70. doi: 10.1186/1479-5876-10-70.
5. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Pensen DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411-22.
6. Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016;17:212-23.
7. Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2b trial. Lancet Oncol. 2011;12:1125-33.
8. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, et al. A phase II study of TG4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with stage III/IV non-small-cell lung cancer. J Thorac Oncol. 2008;3:735-44.
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;19:711-23.
10. Garon EB, Rizvi NA, Hui R, Leighl N, Balmonoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-28.
11. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-35.
12. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627-39.
13. Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-7.
14. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;55:558-62.
15. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909-20.
16. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-20.